. Author manuscript; available in PMC: 2021 Nov 1.

Published in final edited form as: J Biopharm Stat. 2020 Oct 18;30(6):1038–1049. doi: 10.1080/10543406.2020.1832109

Table 1:

Adaptive three-stage design with the total sample size of n = 360 with data generated from models D1-D5. Columns ${\hat{π}}_{U_{1}}$ and $% U$ show the median, 25th and 75th percentiles.

Model	Prevalence of true subgroups	Prevalence of estimated subgroup, ${\hat{π}}_{U_{1}}$	$% U$ of estimated subgroup	Power without enrichment	Power with enrichment	Power with enrichment and futility	Probability to stop for futility
D1	$π_{U_{2}} = 0.60$ $π_{U_{1}} = 0.60$	0.72 (0.60, 0.85)	80 (73, 85)	0.78	0.84	0.84	0.05
D2	$π_{U_{2}} = 0.64$ $π_{U_{1}} = 0.64$	0.72 (0.59, 0.85)	90 (81, 96)	0.73	0.77	0.77	0.07
D3	$π_{U_{2}} = 1.00$ $π_{U_{1}} = 0.21$	0.63 (0.50, 0.78)	70 (62, 73)	0.53	0.60	0.60	0.14
D4	$π_{U_{2}} = 0.46$ $π_{U_{1}} = 0.46$	0.67 (0.56, 0.79)	70 (64, 75)	0.66	0.80	0.79	0.07
D5	$π_{U_{2}} = 1.00$ $π_{U_{1}} = 1.00$	0.77 (0.63, 0.91)	87 (79, 95)	0.81	0.82	0.81	0.05